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Post-traumatic stress disorder (PTSD) is a psychiatric disorder of significant prevalence
and morbidity, whose pathogenesis relies on paradoxical changes of emotional memory
processing. An ideal treatment would be a drug able to block the pathological
over-consolidation and continuous retrieval of the traumatic event, while enhancing
its extinction and reducing the anxiety symptoms. While the latter benefit from
antidepressant medications, no drug is available to control the cognitive symptomatology.
Endocannabinoids regulate affective states and participate in memory consolidation,
retrieval, and extinction. Clinical findings showing a relationship between Cannabis use
and PTSD, as well as changes in endocannabinoid activity in PTSD patients, further
suggest the existence of a link between endocannabinoids and maladaptive brain changes
after trauma exposure. Along these lines, we suggest that endocannabinoid degradation
inhibitors may be an ideal therapeutic approach to simultaneously treat the emotional and
cognitive features of PTSD, avoiding the unwanted psychotropic effects of compounds
directly binding cannabinoid receptors.
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Post-traumatic stress disorder (PTSD) is a psychiatric disorder
of significant prevalence and morbidity (Layton and Krikorian,
2002). In the overall population, more than two thirds of persons
may experience a serious traumatic event at some point in lifetime
(Javidi and Yadollahie, 2012). Although not everyone develops
PTSD after experiencing a traumatic event, the lifetime preva-
lence of PTSD is high, being estimated as 8.2% in Europe and
in the United States, up to 9.2% in Canada (Kessler et al., 1995;
Darves-Bornoz et al., 2008; Van Ameringen et al., 2008). More
than a third of PTSD patients fail to recover even after many
years of treatment (Darves-Bornoz et al., 2008), showing a sig-
nificant impairments in many aspects of health-related quality of
life, including psychosocial functioning (Schelling et al., 1998).
Feeling afraid is a natural response to threats and triggers many
physiological changes to prepare the body to defend against the
danger or to avoid it. In PTSD, this reaction is changed or dam-
aged. Even if anxiety is a common symptom of PTSD patients,
the pathogenesis of the disorder relies on paradoxical changes
of memory processing (Cohen et al., 2006; Parsons and Ressler,
2013). From a physiological point of view, memories character-
ized by a strong emotional salience tend to be well consolidated,
they are often retrieved in our brain and therefore tend not to be
extinct; from an evolutionary perspective, this is of crucial impor-
tance for survival. However, in PTSD patients, all or part of this
processes may become maladaptive. Three symptom categories
characterize the disorder: (1) persistent re-experience of the trau-
matic event; (2) persistent symptoms of increased arousal; and
(3) persistent avoidance of stimuli associated with the trauma,
which may include amnesia for important aspects of the trau-
matic event (Brewin, 2001). These symptoms reflect excessive
retrieval of traumatic memories that are again consolidated, thus
cementing the traumatic memory trace, and retaining its vivid-
ness and power to evoke distress for decades or even a lifetime
(de Quervain et al., 2009). It appears from this symptomatology
that three phases of memory processing may become maladaptive
and of crucial importance in the development and maintenance
of PTSD: consolidation, retrieval, and extinction.
PTSD is heterogeneous in its nature, and often associated
with other psychiatric comorbidities; for these reasons, treating
PTSD is rather difficult, and the disorder may persist over the
patient’s lifetime (Albucher and Liberzon, 2002). The therapeutic
options to treat the anxiety symptoms of PTSD currently include
serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine
reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),
monoamine oxidase inhibitors (MAOi), anticonvulsants, atypi-
cal antipsychotics and benzodiazepines (Albucher and Liberzon,
2002). Although SSRIs emerge as the preferred first line treatment
to treat the anxiety symptoms of PTSD (Dow and Kline, 1997;
Ipser et al., 2006), a large proportion of patients fails to respond
to these medications (Ipser et al., 2006). Furthermore, no suitable
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treatment is currently available to treat the maladaptive cogni-
tive features of PTSD and/or to prevent its development. This
limitation is due to the scarce knowledge of PTSD neurobiology
that hampers the identification of new pharmacological targets
to treat this disorder. As Albucher and Liberzon (2002) pointed
out, the diversity of the symptoms such as flashbacks, nightmares,
hyperarousal, avoidance, numbing, anxiety, anger, impulsivity, or
aggression suggests the involvement of multiple neurotransmitter
systems (Goodman et al., 2012; Packard and Goodman, 2012).
An ideal pharmacological treatment for PTSDwould be a drug
able to block the pathological over consolidation and continuous
retrieval of the traumatic event, while enhancing its extinction
and reducing the anxiety symptoms. Although no such drug is
currently available, recent clinical (Fraser, 2009; Hauer et al.,
2013; Neumeister et al., 2013) and preclinical (Lutz, 2007; Akirav,
2011; Berardi et al., 2012; Ganon-Elazar and Akirav, 2012) studies
point to the endocannabinoid system as a possible ideal therapeu-
tic target to treat both the emotional and cognitive dysfunctions
characterizing PTSD (Neumeister, 2013).
The central endocannabinoid system is a neuroactive lipid sig-
naling system in the brain which shows functional activity since
early stages of brain development; by controlling neurotransmit-
ter release, it plays a relevant role in brain function during both
pre- and post-natal life (Fernandez-Ruiz et al., 2000; Harkany
et al., 2007; Trezza et al., 2008; Campolongo et al., 2009b, 2011).
The endocannabinoid system consists of cannabinoid receptors
(CB1 and CB2), their endogenous lipid ligands (endocannabi-
noids) and the enzymatic machinery for endocannabinoid syn-
thesis and degradation (Piomelli, 2003; Di Marzo et al., 2005).
Due to the wide expression of cannabinoid receptors throughout
limbic regions of the brain, endocannabinoids control both emo-
tional behavior and cognitive processes (Riedel and Davies, 2005;
Campolongo et al., 2007, 2009a; Hill and Gorzalka, 2009; Atsak
et al., 2012; Campolongo et al., 2012). Thus, while preclinical
studies assessing the consequences of cannabinoid receptor block-
ade or activation on emotional responses have yielded sometimes
controversial results, consensus exists that endocannabinoids
have an essential role in maintaining emotional homeostasis
(Haller et al., 2002, 2004; Hill and Gorzalka, 2009; Moreira and
Wotjak, 2010; Parolaro et al., 2010; Ruehle et al., 2012). Similarly,
evidence exists that administration of cannabinoid drugs in ani-
mals influences memory consolidation, retrieval and extinction
(Marsicano et al., 2002; Niyuhire et al., 2007; Marsicano and
Lafenetre, 2009; Atsak et al., 2012; Campolongo et al., 2013).
In particular, systemic administration of cannabinoid agonists
impairs memory retrieval (Niyuhire et al., 2007) while facilitat-
ing memory extinction (Lutz, 2007). Direct evidence has been
provided that endocannabinoids modulate emotional memory
processing acting in the basolateral complex of the amygdala
(BLA), in the hippocampus (de Oliveira Alvares et al., 2005, 2008;
Campolongo et al., 2009a; Atsak et al., 2012) and in the pre-
frontal cortex (Egerton et al., 2006), key brain regions involved
in memory consolidation, retrieval and extinction of emotion-
ally arousing experiences (McGaugh, 2004; Quirk and Mueller,
2008; Roozendaal et al., 2008; Herry et al., 2010), and dysfunc-
tional in PTSD patients (Bremner et al., 2008; Hughes and Shin,
2011). Interestingly, emerging empirical work has indicated a link
between traumatic event exposure and cannabis use. Data from
the National Comorbidity Study demonstrated that adults suf-
fering from PTSD were three times more likely to have cannabis
dependence as compared with those without PTSD (Kessler et al.,
1995). Studies involving military veterans have demonstrated an
even higher rate of cannabis abuse among military veterans with
PTSD (Stewart et al., 1998; Bonn-Miller et al., 2011). A positive
association between PTSD and cannabis use among teenagers has
also been reported (Cornelius et al., 2010). These results could
be partially explained by recent data demonstrating that PTSD
patients present important changes of plasma endocannabinoid
levels and elevation in amygdala-hippocampal-cortico-striatal
CB1 receptor availability (Hauer et al., 2013; Neumeister, 2013;
Neumeister et al., 2013). The comorbidity between cannabis
abuse and PTSD is always described in literature as a nega-
tive aspect, with the increase in substance abuse after a disaster
as a cause for public long-term health consequences. However,
another side of the coin needs to be considered. It is possible that
PTSD patients use cannabis as a self-medication. In support of
this hypothesis, one study among Vietnam veterans indicated that
cannabis use was helpful in managing PTSD symptoms, with par-
ticular respect to the hyperarousal state (Bremner et al., 1996). It
has been shown that there is a correlation between post-traumatic
stress symptom severity and motivation to use marijuana in
order to cope with emotional distress (Bonn-Miller et al., 2007).
Although the majority of the currently available clinical studies
highlights the beneficial effects of cannabis use in PTSD patients,
the positive association between cannabis use and relief from
PTSD symptoms is not an universal finding. Thus, it has also
been documented that, in certain conditions, cannabis abuse may
facilitate PTSD development (Cougle et al., 2011). This may be
due to the fact that direct activation of cannabinoid receptors by
the active ingredient of cannabis Delta-9-tetrahydrocannabinol
leads to a rapid downregulation of the endocannabinoid signal-
ing system (Hirvonen et al., 2012), resulting in tolerance. The
complex scenario that emerges from the clinical setting makes it
difficult to draw final conclusions about the relationship between
cannabis use and PTSD. Preclinical studies allow to control for
the confounding variables that characterize the clinical observa-
tions, and therefore can provide essential information to elucidate
the link between endocannabinoids and emotional memory pro-
cessing, from physiological to pathological conditions. Thus, as
highlighted above, it has been demonstrated that cannabinoid
compounds strongly facilitate memory extinction in animals
(Marsicano et al., 2002; Lutz, 2007), while impairing memory
retrieval (Niyuhire et al., 2007; Atsak et al., 2012). It is thus tempt-
ing to speculate that cannabinoid compounds can attenuate the
excessive retrieval of the traumatic event experienced by PTSD
patients, while facilitating its extinction. Memory consolidation
for emotionally salient events is also affected by cannabinoid
drugs, although the results of the preclinical studies performed so
far are controversial. Thus, it has been shown that post-training
administration of cannabinoid receptor direct or indirect ago-
nists facilitates memory consolidation in the inhibitory avoidance
task (Campolongo et al., 2009a; Hauer et al., 2011). These find-
ings suggest that activation of cannabinoid receptors shortly after
experiencing a stressful event could facilitate the development of
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maladaptive memories of this event. This, in turn, may provide
preclinical rationale to the finding that the use of drugs indirectly
enhancing endocannabinoid activity, such as propofol, or the
use/abuse of cannabis, shortly after the experience of an aversive
event, may facilitate PTSD development in humans and has to be
avoided in the aftermath of an aversive experience (Cougle et al.,
2011; Hemmings and Mackie, 2011; Usuki et al., 2012). However,
cannabinoid agonists administered to rats shortly after exposure
to a series of intense stressful events have been reported to prevent
the impairment in avoidance extinction induced by the traumatic
experience (Ganon-Elazar and Akirav, 2009, 2012, 2013). These
findings leave open the possibility that cannabinoid drugs may be
good candidates for secondary prevention of PTSD, that is, may
be a good therapeutic option immediately after trauma exposure
(Zohar et al., 2011). It clearly appears from this scenario that, if
from one side the data about the effects of cannabinoid drugs
on memory retrieval and extinction are quite consistent and sug-
gest that these compounds may facilitate PTSD recovery, on the
other side the role of cannabinoids in memory consolidation is
still debated. More research is therefore warranted to determine
the extent to which differences in doses, routes of administration,
timing of exposure and behavioral tasks used may be responsible
for the opposite effects of cannabinoid agonists on memory con-
solidation reported so far. Conversely, encouraging clinical data
exist on the use of cannabinoid compounds after the onset of the
pathology (weeks or months after the experience of a traumatic
event, when the memory consolidation of the traumatic event is
completed) (Passie et al., 2012). A recent clinical trial to evalu-
ate the effects of nabilone, a cannabinoid receptor agonist, on
treatment-resistant nightmares in PTSD patients demonstrated
that the majority of patients (72%) receiving nabilone experi-
enced either cessation of nightmares or a significant reduction
in nightmare intensity (Fraser, 2009). Subjective improvement
in sleep time, the quality of sleep, and the reduction of daytime
flashbacks were also noted by some patients (Fraser, 2009). This
is the first report of the use of nabilone for the management
of treatment-resistant nightmares in PTSD. Although this evi-
dence is encouraging, further studies on larger cohorts and
with a more accurate identification of possible side effects of
chronic use of direct cannabinoid agonists are warranted. The
use of drugs that directly bind and activate brain cannabinoid
receptors is indeed limited by their abuse potential (Tanda and
Goldberg, 2003; Economidou et al., 2007; Ashton, 2012). Two
alternative pharmacological approaches exist to target cannabi-
noid receptors in the brain, without inducing abuse liability
(Gobbi et al., 2005; Bortolato et al., 2006; Justinova et al., 2008).
First, it has recently been reported that the non-psychotomimetic
constituent of cannabis cannabidiol facilitates disruption of con-
textual fear memories (Stern et al., 2012) in rats while inducing
anti-anxiogenic-like effects in rats and humans (Bitencourt et al.,
2008; Bergamaschi et al., 2011). Alternatively, several preclinical
studies have identified endocannabinoid deactivation inhibitors
as a novel therapeutic approach for the treatment of neuropsychi-
atric disorders. In particular, indirect cannabinoid agonists have
been proposed as anxiolitic and antidepressant agents (Kathuria
et al., 2003; Bortolato et al., 2006; Piomelli et al., 2006; Vinod and
Hungund, 2006) and have been reported to facilitate extinction of
fear memory in rodents (Bitencourt et al., 2008; Pamplona et al.,
2008). Thus, these compounds may prove effective to ameliorate
the anxiety symptoms of PTSD and, at the same time, an increase
in the endocannabinoid tone may be useful to treat the cognitive
features (Varvel et al., 2007) of the pathology. These dual effects
make these drugs gold candidates in the treatment and preven-
tion of PTSD. Much attention, however, has to be dedicated to
the time framing of pharmacological treatment, with an attempt
to avoid the first early phases of memory consolidation.
It clearly appears that a deeper insight into the role of endo-
cannabinoid neurotransmission in emotional memory process-
ing, both in physiological and pathological conditions, will shed
light in the neurobiological basis of PTSD; this, in turn, will open
new frontiers for alternative and more efficacious therapeutic
approaches for a complete resolution of the pathology.
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